The Role of PegIFN, Bulevirtide, Tenofovir Alafenamide, and Eltrombopag in the Management of Chronic HBV/HDV Co-Infection with Cirrhosis: An Ongoing Clinical Case
<p id="p1">Hepatitis D virus (HDV) is the most severe form of chronic viral hepatitis, accelerating progression to cirrhosis, hepatic decompensation, and hepatocellular carcinoma. Pegylated interferon alfa-2a (PegIFNα) has long been the only option, whereas bulevirtide (BLV) is now approved fo...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2025
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/89835 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: The Role of PegIFN, Bulevirtide, Tenofovir Alafenamide, and Eltrombopag in the Management of Chronic HBV/HDV Co-Infection with Cirrhosis: An Ongoing Clinical Case
- Prevalence and Impact of HBV and HDV Infection Globally and in MENA Region
- HBV & HCV Immunopathogenesis
- Pitfalls in HBV Treatment and Management
- Hepatitis D Virus (HDV): Epidemiology, Transmission, and Advances in Screening and Management
- Toxicidad renal por tenofovir: A propósito de un caso
- Ferret TNF-α and IFN-γ Immunoassays